Increase of macrolide resistance among Streptococcus pyogenes pharyngitis driven by a mef (A)- msr (D)/ emm 2-ST55 lineage in Portugal (2014–2019)
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00968-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Ana Friães und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Microbiologia, Faculdade de Medicina,Universidade de Lisboa, Lisbon, Portugal. Hauptthemen laut MEDLINE: Streptococcus pyogenes, Macrolides, Anti-Bacterial Agents, Pharyngitis. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia.
Abstract (Originalsprache)
Increases in macrolide resistance occurred recently among Streptococcus pyogenes (Group A Streptococcus , GAS) in some countries. While the importance of monitoring the clinical and molecular epidemiology of non-invasive GAS is increasingly recognized, most surveillance focuses on invasive infections, since culture is rarely performed in tonsillo-pharyngitis. We determined the antimicrobial susceptibility and characterized the macrolide-resistant lineages of 2,002 pharyngeal isolates recovered in a Portuguese hospital in 2014–2019. There were seasonal variations in the numbers of recovered isolates, with peaks shifting between March–July and October–December, but consistently low numbers in August and September. Macrolide-resistant and macrolide-susceptible GAS presented independent seasonal and clonal dynamics, with resistant isolates showing lower genetic diversity and minimal overlap with susceptible lineages. Overall, 84 (4%), 77 (4%), and 52 (3%) isolates were resistant to erythromycin, clindamycin, and tetracycline, respectively. Until 2018, macrolide resistance was mainly due to an internationally disseminated emm 77-ST63 lineage carrying erm (A) and tet (O) in ICE Sp2905 and an emm 75-ST49 lineage carrying mef (A)- msr (D) in a novel ɸ1207.3 variant. In 2019, resistance peaked at 9% due to the rapid expansion of mef (A)- msr (D)-positive emm 2-ST55 isolates, replacing previous lineages. Other minor resistant lineages carried mostly erm (B) in a diversity of mobile genetic elements, including emm 75-ST150, emm 9-ST75, emm 11-ST403, emm 12-ST36, emm 76-ST50, and emm 77-ST399 [ erm (T)]. Tetracycline resistance was associated with the genes tet (M) and tet (O), in most cases co-located in the same genetic elements as the erm genes. This study reveals clonal changes among macrolide-resistant GAS driving fluctuations in macrolide resistance and associated phenotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Microbiologia, Faculdade de Medicina,Universidade de Lisboa, Lisbon, Portugal.
- Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal.
- Serviço de Patologia Clínica, Laboratório de Microbiologia, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal.
ORCID-Profile: Ana Friães, Rafael Mamede, José Melo-Cristino, Mario Ramirez
Förderung
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Friães, A., Mamede, R., Santos, B., Marrão, G., Melo-Cristino, J., & Ramirez, M. (2025). Increase of macrolide resistance among Streptococcus pyogenes pharyngitis driven by a mef (A)- msr (D)/ emm 2-ST55 lineage in Portugal (2014–2019). Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00968-25
Vancouver
Friães A, Mamede R, Santos B, Marrão G, Melo-Cristino J, Ramirez M. Increase of macrolide resistance among Streptococcus pyogenes pharyngitis driven by a mef (A)- msr (D)/ emm 2-ST55 lineage in Portugal (2014–2019). Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00968-25
BibTeX
@article{Fries2025,
author = {Friães, Ana and Mamede, Rafael and Santos, Beatriz and Marrão, Gina and Melo-Cristino, José and Ramirez, Mario},
title = {Increase of macrolide resistance among Streptococcus pyogenes pharyngitis driven by a mef (A)- msr (D)/ emm 2-ST55 lineage in Portugal (2014–2019)},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00968-25}
}
EUVIMED